Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 16, 2006 Jim Fink	The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007.
The Motley Fool December 1, 2008 Zoe Van Schyndel	A Better Way to Invest in Biotech? Structured as a trust, the Biotech HOLDR holds common stock of companies in the biotechnology industry. But don't confuse HOLDRs with exchange-traded funds.
The Motley Fool April 4, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry.
The Motley Fool June 15, 2011 Selena Maranjian	Make Money in Biotech the Easy Way There's no need to guess which biotech company will perform best with the SPDR S&P Biotech ETF.
The Motley Fool May 5, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry.
The Motley Fool October 26, 2011 Selena Maranjian	Make Money in Promising Biotech Stocks the Easy Way If you expect the biotech industry to thrive as scientists develop more drugs to treat our aging population, the iShares Nasdaq Biotechnology ETF could be for you.
BusinessWeek June 13, 2005 Arlene Weintraub	Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances.
Investment Advisor April 2010 Vaughan Scully	The ETF Advisor: Prospects for Healthcare ETFs Better Than Those for Reform There are about two dozen exchange traded funds that offer a wide variety of exposures to the healthcare sector, including broad-based, global, and leveraged ETFs, as well as those targeting individual industries.
The Motley Fool February 23, 2005 Brian Gorman	Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies.
The Motley Fool October 26, 2010 Selena Maranjian	Make Money in Biotech the Simple Way These ETFs present an easy way to invest in biotechnology.
BusinessWeek May 14, 2007 Lewis Braham	A Two-Way Wager On Commodities Rydex' new fund allows investors to play the ups and downs of the futures market.
Inc. May 1, 2002 Kenneth Klee	The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...
Entrepreneur May 2006 Dian Vujovich	Have No Fear If the word leverage doesn't create a deer-in-headlights gaze when you hear it, then you may like ProFunds.
The Motley Fool June 7, 2011 Selena Maranjian	Make Money in Large Caps the Better Way There's no need to guess which company will perform best when you can invest in 500 all at once.
The Motley Fool December 18, 2007 Dan Caplinger	Improving on Index Funds As the fund universe continues to evolve, new funds have emerged that try to improve on their first-generation counterparts. One fund in particular has its sights set high -- the Rydex S&P Equal Weight ETF.
The Motley Fool July 25, 2008 Zoe Van Schyndel	Don't Bank on These Funds The returns of the three funds outlined below are symptomatic of the abysmal performance in the banking sector overall. Each has lost 40% or more of its value over the past three years.
The Motley Fool January 31, 2007 Zoe Van Schyndel	Health Care, Thinly Sliced Five new health-care-focused ETFs, the HealthShares family, provide increasingly specific ways to invest in health care.
The Motley Fool April 9, 2010 Brian Orelli	Double Your Biotech Returns! Really! Taking a closer look at leveraged biotech ETFs.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
The Motley Fool July 30, 2004 Roger Nusbaum	Gilead Keeps Rolling Along Biotech can be a tough place to invest, but Gilead Sciences offers relative stability.
Financial Advisor August 2006 Matthew Hougan	Too Much Of A Good Thing? Do the new leveraged ETFs have a place in the financial advisor's toolbox?
The Motley Fool May 19, 2004 Roger Nusbaum	Gilead Shines This biotech company looks strong because investors can relate to its products.
The Motley Fool April 4, 2005 John Reeves	Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier.
Bio-IT World February 2006 G. Steven Burrill	Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006...
BusinessWeek November 10, 2003 Arlene Weintraub	Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
BusinessWeek June 13, 2005	Biotech's "Fantastic Future Ahead" Some bold predictions on what's coming for the biotech industry from Ernst & Young's Scott Morrison.
The Motley Fool November 15, 2011 Selena Maranjian	Make Money in Biotech and Genome Stocks the Easy Way If you expect biotech firms and companies specializing in genomics to thrive as advances in health care and medicine continue, the PowerShares Dynamic Biotech & Genome ETF could save you a lot of trouble.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
The Motley Fool July 21, 2005 Tom Taulli	Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey.
The Motley Fool February 28, 2011 David Williamson	Don't Miss These Health-Care ETFs Two ways ETFs can help your portfolio
Financial Advisor September 2004 Marla Brill	A Biotechnology Fund On Sedatives Eaton Vance's Worldwide Health Sciences Fund manager Sam Isaly takes some nail biting out of biotech investing.
Investment Advisor August 2006	S&P Mutual Fund Sector Focus: Health Care Funds Tired and Sluggish Big pharma names dominate most health care funds and these businesses are beset with problems. One of the best longer-term performers in this area, the $561-million Schwab Health Care Fund.
Registered Rep. March 1, 2008 Stan Luxenberg	To Short An ETF The increasing variety of ETFs has made it possible to short in ways that could not be done when the Internet bubble burst.
The Motley Fool August 17, 2004 Charly Travers	Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector.
Managed Care May 2004	Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs.
Bio-IT World May 2006 G. Steven Burrill	Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies.
The Motley Fool October 26, 2006 Shannon Zimmerman	A Great First Investment At some point in our investing careers, we're all newbies. Looking to make a smart investing start? Try: the Rydex S&P Equal Weight exchange-traded fund.
Bio-IT World August 2005 G. Steven Burrill	Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market.
Entrepreneur August 2008 Farnoosh Torabi	On The Upside The economy may be heading downhill, but for short funds, things are looking up.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool August 26, 2008 Selena Maranjian	A Questionable Top-10 List Do these funds really belong in your portfolio? Take a look to see if you own any of these questionable funds.
The Motley Fool May 20, 2011 Selena Maranjian	Beware These "Very Attractive" ETFs There are some big red flags here.
The Motley Fool July 12, 2004 Brian Gorman	India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers.
Investment Advisor February 2010 Vaughan Scully	The ETF Advisor: S&P 500 ETFs While some S&P 500 Index funds are virtually identical to the SPDR fund, a handful of other ETFs offers more substantial modifications to the original formula.
The Motley Fool August 10, 2004 Brian Gorman	Biotech Cost Control Will the high cost of therapies slow sales in the sector? Investors can avoid problems by paying close attention to companies' pipelines and reimbursement trends.
Bio-IT World Jul/Aug 2006 John Russell	Burrill's Biotech 2006 G. Steven Burrill's Biotech 2006 -- Life Sciences: A Changing Prescription is his 20th annual report on the industry. This longtime market watcher and biotech investment banker has pulled together a kind of whirlwind tour of biotech finances, markets, and technologies.
The Motley Fool July 14, 2005 Stephen D. Simpson	Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great."
The Motley Fool December 16, 2003 David Nierengarten	Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks.